The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.
April 10th 2024
Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Review: More Research Needed on Immune System to Understand PAH Pathobiology
November 20th 2021While research has examined the implications of the immune system and its contributions to pulmonary arterial hypertension, further research is required to understand the pathobiology of the condition.
Read More
Study Determines PAH-SYMPACT Suitable for Use Among Patients With SAPH
November 19th 2021A new study aiming to understand sarcoidosis-associated pulmonary hypertension symptoms and their impacts on patients’ lives determined that the Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire could be used to suitably assess patients.
Read More
Patients With CTEPH Have Worse Baseline HRQOL Than Patients With IPAH
November 6th 2021At baseline, patients with chronic thromboembolic pulmonary hypertension (CTEPH) had worse health-related quality of life (HRQOL) than patients with idiopathic pulmonary arterial hypertension (IPAH), but over time the scores were similar.
Read More
Triplet Therapy for PAH May Reduce Disease Progression vs Doublet Therapy
October 6th 2021New data on treatment for newly diagnosed pulmonary arterial hypertension (PAH) show initial treatment for the progressive disease that includes macitentan has potential to reduce risk of disease progression.
Read More
Oral Selexipag Offers New Therapy Option in PAH-CHD, Case Reports Show
May 18th 2021A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral prostacyclin.
Read More
New Analysis Identifies Prognostic Indicators in Pulmonary Hypertension Secondary to HFrEF
May 13th 2021Right ventricular end-systolic elastance to end-systolic arterial elastance coupling in excess of 0.68 was linked with preserved right ventricular function and better survival outcomes in patients with heart failure with reduced ejection fraction and secondary pulmonary hypertension.
Read More
Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy
April 21st 2021While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.
Read More
PAH Treatment Patterns and Costs Related to Hospitalization
April 15th 2021New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).
Read More
Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment
April 13th 2021A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
Read More
Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization
April 6th 2021Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.
Read More
Iron Replacement Has No Impact on Disease Severity, Quality of Life in PAH
April 1st 2021Idiopathic pulmonary arterial hypertension (PAH) is associated with iron deficiency, which is in turn associated with worse functional capacity and survival in PAH; however, iron repletion by infusion provided no significant clinical benefit.
Read More
Survey Finds Unmet Needs Despite Good HRQOL for Patients With PAH
March 21st 2021Despite patients with pulmonary arterial hypertension reporting good quality of life and low symptom severity, functional limitations persisted, suggesting improvements to the patient experience are needed, according to researchers.
Read More
Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes
March 18th 2021Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.
Read More
Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy
March 7th 2021Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.
Read More